IP Library Granted Patent US 11,781,179
Granted Patent B2
US 11,781,179 · App. 16/897,588 · Granted Oct 10, 2023

Methods for determining a nucleotide sequence contiguous to a known target nucleotide sequence

Inventors: Anthony John Iafrate (Newton, MA); Long Phi Le (Boston, MA); Zongli Zheng (Boston, MA)
Assignee: THE GENERAL HOSPITAL CORPORATION
C12Q1/6855C12Q1/6806C12Q1/6874C12Q2525/155C12Q2525/161C12Q2525/191C12Q2531/113C12Q2549/119
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,781,179
App. No.
16/897,588
Granted
Oct 10, 2023
Kind
B2
Abstract

The technology described herein is directed to methods of determining oligonucleotide sequences, e.g. by enriching target sequences prior to sequencing the sequences.

Claims (21)

1. A method for determining a nucleotide sequence, the method comprising:

(a) amplifying a nucleic acid template comprising a 3′-end comprising a known target nucleotide sequence, a first nucleotide sequence contiguous to the known target nucleotide sequence, and a 5-end comprising an amplification strand of a ligated universal oligonucleotide tail-adaptor, using (i) a first primer that comprises a nucleotide sequence identical to a 5′ portion of a first sequencing primer and (ii) a second primer that anneals to the 3-end of the nucleic acid template comprising the known target nucleotide sequence, thereby generating a first amplification product comprising the first nucleotide sequence and the known target nucleotide sequence;

(b) amplifying the first amplification product of (a) using (i) a third primer that comprises a nucleotide sequence identical to a portion of the first sequencing primer and is nested relative to the first primer and (ii) a fourth primer that comprises a 5′ portion comprising a nucleic acid sequence that is identical to a second sequencing primer, anneals to a 3′ portion of the first amplification product comprising the known target nucleotide sequence, and is nested relative to the second primer, thereby generating a second amplification product; and

(c) determining the sequence of the first nucleotide sequence in the second amplification product.

2. The method of claim 1 , wherein step (c) comprises sequencing the second amplification product using at least the first sequencing primer.

3. The method of claim 2 , wherein the sequencing of the second amplification product further comprises using a second sequencing primer substantially identical to a portion of the fourth primer.

4. The method of claim 1 , wherein the amplification strand comprises a barcode portion and the second amplification product comprises the barcode portion.

5. The method of claim 1 , wherein the first nucleotide sequence comprises a genetic alteration.

6. The method of claim 1 , wherein the nucleic acid template comprises DNA.

7. The method of claim 1 , wherein the first nucleotide sequence comprises an insertion or deletion.

8. The method of claim 1 , wherein the nucleic acid template comprises cDNA.

9. The method of claim 1 , wherein the second primer comprises a 3′-end substantially complementary to the known target nucleotide sequence and a 5′ tag sequence portion comprising a GC content of at least 65%.

10. The method of claim 1 , wherein the known target nucleotide sequence and/or the first nucleotide sequence comprises a sequence comprising a gene rearrangement.

11. The method of claim 10 , wherein the gene rearrangement comprises a fusion oncogene.

12. The method of claim 1 , wherein the nucleic acid template is prepared from a sample obtained from a subject having a condition associated with a genetic alteration.

13. The method of claim 1 , wherein the known target nucleotide sequence and/or the first nucleotide sequence comprises a sequence from a gene selected from the group of: anaplastic lymphoma kinase (ALK); c-ros oncogene 1 (ROS1); and rearranged during transfection (RET).

14. A method for determining a nucleotide sequence, the method comprising:

(a) ligating an amplification strand of a universal oligonucleotide tail-adaptor to a 5′-end of a nucleic acid template comprising (i) a 3-end comprising a known target nucleotide sequence and (ii) a first nucleotide sequence contiguous to the known target nucleotide sequence;

(b) amplifying the nucleic acid template using (i) a first primer that comprises a nucleotide sequence identical to a 5′ portion of a first sequencing primer and (ii) a second primer that anneals to the 3′-end of the nucleic acid template comprising the known target nucleotide sequence, thereby generating a first amplification product comprising the first nucleotide sequence and the known target nucleotide sequence;

(c) amplifying the first amplification product of (b) using (i) a third primer that comprises a nucleotide sequence identical to a portion of the first sequencing primer and that is nested relative to the first primer and (ii) a fourth primer that comprises a 5′ portion comprising a nucleic acid sequence that is identical to a second sequencing primer, anneals to a 3′ portion of the first amplification product comprising the known target nucleotide sequence and is nested relative to the second primer, thereby generating a second amplification product comprising the first nucleotide sequence; and

(d) determining the sequence of the first nucleotide sequence in the second amplification product by a process comprising next-generation sequencing.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2023
From: IAFRATE, ANTHONY JOHN; LE, LONG PHI; ZHENG, ZONGLI
To: THE GENERAL HOSPITAL CORPORATION
Reel/Frame 062895/0449 →
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2021
From: PERCEPTIVE CREDIT HOLDINGS III, LP
To: ARCHERDX, LLC
Reel/Frame 056069/0305 →
PATENT SECURITY AGREEMENT Recorded Oct 6, 2020
From: ARCHERDX, LLC
To: PERCEPTIVE CREDIT HOLDINGS III, LP
Reel/Frame 053992/0919 →
MERGER AND CHANGE OF NAME Recorded Oct 2, 2020
From: ARCHERDX, INC.; APOLLO MERGER SUB B LLC
To: ARCHERDX, LLC
Reel/Frame 053965/0492 →
Cited By (1)
US 12,630,864